Physician profile
Tara Difabio
NPI 1730320417
$2,644.49
in general payments reported to CMS, 2019-2025
46 companies · $61.50 in 2025
The $61.50 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $656 · 2023: $713 · 2024: $572 · 2025: $61.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.82 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $245.36 | 2022-2024 | Padcev |
| Incyte Corporation | $197.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $173.15 | 2021-2023 | Opdivo |
| Janssen Biotech, INC. | $156.03 | 2021-2024 | Tecvayli, Talvey, Darzalex |
| Boston Scientific Corporation | $113.45 | 2024-2025 | Farapulse |
| Astrazeneca Pharmaceuticals Lp | $111.72 | 2022-2024 | Enhertu, Lynparza, Calquence |
| Seagen INC. | $96.84 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Lilly USA, LLC | $94.28 | 2021-2024 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $93.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.99 | 2023-2024 | |
| Amgen INC. | $83.78 | 2021-2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $81.84 | 2022-2024 | Alunbrig, Fruzaqla, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $78.98 | 2021-2023 | Imbruvica |
| Eisai INC. | $77.15 | 2021-2023 | |
| Abbvie INC. | $72.43 | 2021-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Difabio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.